BioSpace News Archive

MicroConstants, Inc., a leader in bioanalytical testing services, announced that it has signed an agreement with BioAgilytix Labs, a leading global contract research organization (CRO) focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development.

Ginkgo Bioworks today announced a revenue and business update for the first half of 2021.

KemPharm, Inc. announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the Audit Committee.

Glaucoma Research Foundation (GRF), the nation’s oldest and largest non-profit organization dedicated to funding research to find a cure for glaucoma, today announced the receipt of a $1.5 million matching gift from Steve and Michele Kirsch of Palo Alto, California.

Cortexyme, Inc. will participate as a featured speaker covering its pivotal Phase 2/3 GAIN Trial

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Lini Pandite, MBChB, MBA to its board of directors.

Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has signed a drug manufacture contract with Aurigene Pharmaceutical Services, India, a subsidiary of Dr Reddy’s Laboratories Limited (NYSE: RDY; BSE: 500124).

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the ROSA® Hip System for robotically-assisted direct anterior total hip replacement.

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI.

Henlius announced Half-Year results ended June 30th, 2021, sharing the company’s recent noteworthy progress and achievements.